Glaukos intraocular implant gets FDA review

• The US FDA has accepted a New Drug Application from Glaukos Corp. (NYSE:GKOS) for iDose TR (travoprost intraocular implant) for the treatment of open-angle glaucoma and ocular hypertension.
• The agency action date is Dec. 22.
• Glaukos (GKOS) supported its application with two phase 3 trials. They showed that iDose TR led to pre-specified primary efficacy endpoints through three months and a favorable tolerability and safety profile through 12 months.

More on Glaukos

• Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

• Glaukos: Show Me The Money